Their findings using a murine myeloproliferative neoplasm (MPN) model indicate that treatment with a selective JAK2 inhibitor attenuates the MPN phenotype by diminishing the myeloid progenitor population. The gene discussed is JAK2; the disease is myeloproliferative disorder.